SEC Form 4 · accession 0000891293-16-000094
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Chief Business Officer
Period of report
Feb 4, 2016
Accepted (ET)
Feb 5, 2016 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2016 | S | 400 | $1.14 | D | 609,684 | D | |
| Common Stock | Feb 4, 2016 | S | 5,000 | $1.15 | D | 604,684 | D | |
| Common Stock | Feb 4, 2016 | S | 3,000 | $1.155 | D | 601,684 | D | |
| Common Stock | Feb 4, 2016 | S | 600 | $1.16 | D | 601,084 | D | |
| Common Stock | Feb 4, 2016 | S | 700 | $1.17 | D | 600,384 | D | |
| Common Stock | Feb 4, 2016 | S | 300 | $1.175 | D | 600,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.